Quick Listen: Scrip’s Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: a ground-breaking approval for Alzheimer’s in the US; LAG-3 inhibitors and new Keytruda data generate excitement at ASCO; and clinical progress for another COVID-19 vaccine.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 11 June 2021, including: a ground-breaking approval for Alzheimer’s in the US; LAG-3 inhibitors and new Keytruda data generate excitement at ASCO; and progress for another COVID-19 vaccine.
These and all other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud and TuneIn - and also now on Spotify Podcasts - and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Biogen/Eisai Win On Aduhelm Approval Bet And Wager Next On Price" - Scrip, 7 Jun, 2021.)
(Also see "With Aduhelm Out Of The Gate, Biogen Focuses On Clearing Commercial Bottlenecks" - Scrip, 8 Jun, 2021.)
(Also see "ASCO Offers Glimpse Of LAG-3 Inhibitors’ Potential Opportunities – And Limitations" - Scrip, 7 Jun, 2021.)
(Also see "Keytruda Adjuvant Kidney Cancer Data Cement The Future Of IO" - Scrip, 6 Jun, 2021.)
(Also see "Valneva Seeks Covid Vaccine Approval On AstraZeneca Head-To-Head Data Alone" - Scrip, 4 Jun, 2021.)